Atara expands global tab-cel partnership up to $640M with Pierre Fabre

Atara Biotherapeutics reported recent business highlights including an expanded global partnership with Pierre Fabre Laboratories for tabelecleucel tab-cel , financial results for the third quarter 2023, and key upcoming catalysts. “We are proud to expand our global tab-cel partnership with Pierre Fabre Laboratories, who is committed to delivering this first-of-its-kind treatment to patients in need across the globe,” said Pascal Touchon, President and Chief Executive Officer of Atara. “In light of our expanded tab-cel partnership and to strategically position the company going forward, we are also restructuring our operations to significantly reduce expenses, meaningfully extend our cash runway to nearly two years, and enable organizational focus on generating the greatest value from our transformative pipeline: ATA188 and our differentiated allogeneic CAR-T assets. I wish to personally thank the talented colleagues who will be departing Atara for their essential contributions in getting us to this critical point in our journey.” Atara has entered into an expanded partnership with Pierre Fabre Laboratories for the U.S. and remaining global commercial markets for tab-cel for up to $640M and significant double-digit tiered royalties on net sales. In addition, Pierre Fabre Laboratories has agreed to reimburse Atara for expected tab-cel global development costs through Biologics License Application BLA transfer, and purchase current and future tab-cel inventory through the BLA transfer date. Near-term payments to Atara include: Approximately $30M in cash upfront and initial inventory purchase at closing $100M in potential regulatory milestones through BLA approval…Atara expects to submit the tab-cel post-transplant lymphoproliferative disease PTLD BLA in Q2 2024 “We are eager to progress tabelecleucel toward approval in the U.S. so that American patients can access this innovative treatment already approved and commercialized in Europe,” said Eric Ducournau, CEO of Pierre Fabre Laboratories. .